1 / 55

Grade 1-2 Follicular Lymphoma

Follicular Lymphoma: Updates on Treatment Strategies Daryl Tan Raffles Cancer Center Visiting Consultant Singapore General Hospital Adjunct Assistant Professor, Duke-NUS Graduate Medical School. Grade 1-2 Follicular Lymphoma. Limited Stage. Advanced Stage, Stage II bulky or ‘ B ’.

elden
Download Presentation

Grade 1-2 Follicular Lymphoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Follicular Lymphoma: Updates on Treatment StrategiesDaryl TanRaffles Cancer CenterVisiting Consultant Singapore General HospitalAdjunct Assistant Professor,Duke-NUS Graduate Medical School

  2. Grade 1-2 Follicular Lymphoma Limited Stage Advanced Stage, Stage II bulky or ‘B’ GELF Criteria Symptomatic, High tumor burden Asymptomatic, Low tumor burden Curative Intent Radiotherapy Chemotherapy/ Immunotherapy Watch and Wait Clinical Questions : • Is there still a role for watch and wait in rituximab era? • What is the optimal frontline therapy? Which R-Chemo? • Role of maintenance rituximab? CR or PR Consolidation RIT or Maintenance Rituximab

  3. Grade 1-2 Follicular Lymphoma Advanced Stage, Stage II bulky or ‘B’ Asymptomatic, Low tumor burden Watch and Wait Clinical Questions : • Is there still a role for watch and wait in rituximab era?

  4. Watch and Wait in FL Horning S, SA Rosenberg. NEJM 1984;311:1471-76

  5. Overall Survival of 1,333 FL Patients at Stanford by Time to First Treatment P<0.001 Tan D, Horning S, et al. ASH 2007. Abstract 3428

  6. Median FU: 32 months

  7. Time To Initiation of New Therapy Ardeshna KM et al. ASH 2010 Abstract 6

  8. Grade 1-2 Follicular Lymphoma Advanced Stage, Stage II bulky or ‘B’ Asymptomatic, Low tumor burden Watch and Wait Clinical Questions : • Is there still a role for watch and wait in rituximab era? • Role of maintenance rituximab?

  9. wks • progression within 6 months of Rtx • failure to respond to Rtx • inability to complete protocol • initiation of alternative therapy.

  10. RESORT: Time to First Cytotoxic Therapy 3-yr Freedom from First Cytotoxic Chemo MR: 95% RR: 86% Median FU : 3.8 yrs

  11. Ave Doses of Rtx Received 4.5 15.8

  12. Grade 1-2 Follicular Lymphoma Advanced Stage, Stage II bulky or ‘B’ Symptomatic, High tumor burden Clinical Questions : • Is there still a role for watch and wait in rituximab era? • What is the optimal frontline therapy? • Role of maintenance rituximab? Chemotherapy/ Immunotherapy

  13. RCTs on R-Chemo vs Chemo Marcus et al Salles et al Which R-Chemo for induction ? Hiddeman et al Harold et al

  14. Phase III Study of R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: final results of the FOLL05 trial from the FondazioneItalianaLinfomi (N=534) Federico M, et al. ASCO 2012: Abstract 8006

  15. Time-to-Treatment Failure (R-CHOPvsR-CVPvsR-FM) Federico M, et al. ASCO 2012: Abstract 8006

  16. Adverse Events (≥grade 3) (R-CHOP vs R-CVP vs R-FM) Second Malignancies: 2% 3% 8% Federico M, et al. ASCO 2012: Abstract 8006

  17. Bendamustine-Rituximab (B-R) vs CHOP-R StiL NHL 1-2003 • Bendamustine-Rituximab • (N=139) • - Bendamustine 90 mg/m2 day 1+2 • Rituximab 375 mg/m2 day 1 Follicular Waldenström’s Marginal zone Small lymphocytic Mantle cell (elderly) R • CHOP-Rituximab (N=140) • - Cyclophosphamide 750 mg/m2 day 1 • - Doxorubicin 50 mg/m2 day 1 • - Vincristine 1.4 mg/m2 day 1 • Prednisone 100 mg days 1-5 • Rituximab 375 mg/m2 day 1 Median follow-up 45 months Lancet 2012, accepted for publication; J Clin Oncol 30, 2012 (suppl; abstr 3) Courtesy of Mathias Rummel

  18. Worst CTCAE Grades for Hematology Tests Results Number (%) of patients Treatment group Grade 2 Grade 3 Grade 4 Grade 3-4 Leukocytes CHOP-R 39 (15) 110 (44) 71 (28) 181 (72) (109/L) B-R 80 (30) 85 (32) 13 (5) 98 (37) Neutrophils CHOP-R 19 (8) 70 (28) 103 (41) 173 (69) (109/L) B-R 61 (23) 53 (20) 24 (9) 77 (29) Lymphocytes CHOP-R 72 (29) 87 (35) 19 (8) 106 (43) (109/L) B-R 38 (14) 122 (46) 74 (28) 196 (74) Hemoglobin CHOP-R 84 (33) 10 (4) 2 (<1) 12 (5) (g/L) B-R 44 (16) 6 (2) 2 (<1) 8 (3) Platelets CHOP-R 20 (8) 11 (4) 5 (2) 16 (6) (109/L) B-R 19 (7) 15 (6) 2 (<1) 13 (5) Courtesy of Mathias Rummel

  19. Toxicities(all CTC-grades) B-R (n=261) CHOP-R (n=253) (no. of pts) (no. of pts)P value Alopecia - +++ < 0.0001 Paresthesias 18 73 < 0.0001 Stomatitis 16 47 < 0.0001 Skin (erythema) 42 23 = 0.0122 Allergic reaction (skin) 40 15 = 0.0003 Infectious complications 96 127 = 0.0025 - Sepsis 1 8 = 0.0190 Courtesy of Mathias Rummel

  20. Results Response rates B-R CHOP-R(n=261) (n=253) P value ORR 92,7 % 91,3 % CR 39,8 % 30,0 % = 0.021 SD 2,7 % 3,6 % PD 3,5 % 2,8 % Lancet 2012 in press; J Clin Oncol 30, 2012 (suppl; abstr 3)

  21. Median (months) B-R n. y. r. CHOP-R 40.9 PFS: follicular (n=279) 45 months follow-up 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 Hazard ratio, 0.61 (95% CI 0.42 - 0.87) p = 0.0072 0.1 0.0 0 12 24 36 48 60 72 84 96 months Courtesy of Mathias Rummel

  22. Median (months) B-R n. y. r. CHOP-R 46.6 PFS: follicular, FLIPI low (0-2) (n=152; 54.5%) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 Hazard ratio, 0.56 (95% CI 0.31 - 0.98) p = 0.0428 0.1 0.0 0 12 24 36 48 60 72 84 96 months Courtesy of Mathias Rummel

  23. Median (months) B-R 53.4 CHOP-R 34.9 PFS: follicular, FLIPI high (3-5) (n=127; 45.5%) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 Hazard ratio, 0.63 (95% CI 0.38 - 1.04) p = 0.0679 0.1 0.0 0 12 24 36 48 60 72 84 96 months Courtesy of Mathias Rummel

  24. Median (months) B-R 53.6 CHOP-R 31.5 Age: 61 yrs and older ( n = 315 ) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 Hazard ratio, 0.62 (95% CI 0.45 - 0.84) p = 0.0022 0.1 0.0 0 12 24 36 48 60 72 84 96 months Courtesy of Mathias Rummel

  25. Median (months) B-R 71.6 CHOP-R 30.9 Age: 60 yrs and younger ( n = 199 ) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 Hazard ratio, 0.52 (95% CI 0.33 - 0.79) p = 0.0022 0.1 0.0 0 12 24 36 48 60 72 84 96 months Courtesy of Mathias Rummel

  26. Overall survival 1.0 0.9 0.8 B-R 0.7 0.6 CHOP-R 0.5 0.4 2 yrs 3 yrs 4 yrs 5 yrs 6 yrs 7 yrs 89.7% 85.6% 82.3% 80.1% 80.1% 75.9% 89.5% 86.7% 84.2% 77.8% 75.5% 59.5% 0.3 0.2 0.1 0.0 0 12 24 36 48 60 72 84 96 months Courtesy of Mathias Rummel

  27. Grade 1-2 Follicular Lymphoma Advanced Stage, Stage II bulky or ‘B’ Symptomatic, High tumor burden Clinical Questions : • Is there still a role for watch and wait in rituximab era? • What is the optimal frontline therapy? • Which R-Chemo ? BR >RCHOP> RCVP • DO WE REALLY NEED CHEMO UPFRONT ? • Role of maintenance rituximab? • What is the optimal sequence of treatment? Chemotherapy/ Immunotherapy

  28. ?

  29. The Kiss of Death in Follicular Lymphoma CTL: Cytotoxic T lymphocyte, FL: follicular lymphoma Ramsay, et al. The Kiss of Death in FL. Blood 2011; 118: 5365-5366 Laurent, et al. Distribution, function, and prognostic value of cytotoxicT lymphocytes in FL. Blood 2011;118(20):5371-5379

  30. Lenalidomide:Mechanisms of Action in Lymphoma Ramsay AG, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114(21):4713-4720. Lei W, et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells. Clin Cancer Res 2008;14:4650-4657

  31. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study Nathan Fowler, SattvaNeelapu, Frederick Hagemeister, Peter McLaughlin, Larry W Kwak, Jorge Romaguera, Michele Fanale, Luis Fayad, Robert Orlowski, Michael Wang, Francesco Turturro, Yasuhiro Oki, Linda Lacerte, Felipe Samaniego Department of Lymphoma/Myeloma MD Anderson Cancer Center, Houston, Texas Courtesy of Nathan Fowler

  32. Study Design 7 8 9 10 11 12 Lenalidomide 20mg Days 1-21 Cycles 1-6* Months 1 2 3 4 5 6 Lenalidomide 20mg Days 1-21 Cycles 7-12* Rituximab 375mg/M2 Day 1 of Cycles 1-6 Rituximab 375mg/M2 Day 1 of Cycles 7-12 R R R= RESTAGING R R If clinical benefit, can proceed to 12 cycles *SLL patients: Dose escalation of lenalidomide starting with cycle 1: (10mg, 15mg, 20mg) • Phase II, single institution • Planned Enrollment • N= 50 Follicular lymphoma (grade I/II) • N=30 Small lymphocytic lymphoma • N=30 Marginal zone lymphoma • Groups analyzed independently for response and toxicity

  33. Response Rates • *7 pts not evaluable for response: • 5 due to adverse event in cycle 1 • 1 due to non-compliance • 1 due to withdrawal of consent Courtesy of Nathan Fowler

  34. Progression Free Survival All Evaluable Patients N=103 36 mo PFS*:78% *Projected 3 year PFS Courtesy of Nathan Fowler

  35. Grade ≥ 3 Hematologic Toxicity 5 patients developed grade 3 neutropenic fever

  36. Grade ≥ 3 Non Hematologic Adverse Events (>1 pt.) • Five secondary malignancies reported • 75 yo: recurrent bladder cancer • 53 yo: localized melanoma • 53 yo: stage 0 DCIS of breast • 81 yo: multiple myeloma • 75 yo: recurrent localized prostate cancer

  37. RELEVANCE Study Design(Rituximab and LEnalidomide versus Any ChEmotherapy) R2 R2 Maintenance 1st line FL N=1000 R R+ Chemo RituximabMaint. • R+Chemo: • Investigator’s choice of R-CHOP, R-CVP, BR • Lenalidomide 20mg for 6 cycles, then 10mg if CR • LYSA (PI: Morschhauser) + North America (PI: Fowler) Courtesy of Nathan Fowler

  38. Grade 1-2 Follicular Lymphoma Advanced Stage, Stage II bulky or ‘B’ Symptomatic, High tumor burden Chemotherapy/ Immunotherapy Clinical Question : • Role of maintenance rituximab? CR or PR Consolidation RIT or Maintenance Rituximab

  39. R-Maintenance vs Observation After R-Chemo Induction (PRIMA) Salles G, et al. Lancet 2010; 377: 42–51

  40. Median follow-up: 36 months Time to next lymphoma treatment Progression Free Survival 75% 58% Overall Survival Time to next Chemotherapy Salles G, et al. Lancet 2010; 377: 42–51

  41. Grade 3 / 4 Adverse Events P=0.0026 Fulminant Hep B (n=1) Salles G, et al. Lancet 2010; 377: 42–51

  42. Conclusions-BTG 2013 • Certainly still a role for watchful waiting • R-FM a/w increased toxicity • B-R is less toxic and more effective than CHOP-R • Impressive data with frontline IMiD + R • Maintance rituximab • Observed improvements in PFS and Time to Next Tx not been shown to translate into OS benefit • MR should be weighed against increased risk of toxicity, other potential complications, resources and pt’s preference

  43. Thank You

More Related